Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Online weight loss injections are prescription GLP-1 or GIP/GLP-1 medicines, such as semaglutide and tirzepatide, prescribed through telehealth after a clinical evaluation and shipped to your home. Licensed providers review BMI, health history, medications, contraindications, and safety risks before prescribing FDA-approved or compounded options for subcutaneous injection [1,2,8].
What is an online weight loss injection?
Online weight loss injection usually means a prescription injectable medicine used for chronic weight management after a telehealth visit. The most common options are GLP-1 receptor agonists and GIP/GLP-1 dual agonists, which affect appetite, fullness, stomach emptying, and blood-sugar signaling [1,2,5,6].
A subcutaneous injection means the medicine is injected under the skin. For FDA-approved semaglutide and tirzepatide weight-management products, the labeled schedule is once weekly; for liraglutide, the FDA label describes once-daily injection [1,2,3].
How GLP-1 injections cause weight loss
GLP-1 receptor agonists copy or enhance signals from glucagon-like peptide-1, a gut hormone involved in appetite, insulin release, and stomach emptying after meals [1,4,5]. Tirzepatide is a GIP/GLP-1 dual agonist, meaning it activates glucose-dependent insulinotropic polypeptide and GLP-1 receptors [2,6].
In clinical trials, semaglutide and tirzepatide were linked with greater average weight loss than placebo, but individual results vary [5,6]. These possible benefits must be weighed against common side effects such as nausea, vomiting, diarrhea, constipation, and abdominal pain, plus label warnings for pancreatitis, gallbladder disease, kidney injury from dehydration, and thyroid C-cell tumor risk [1,2].
Brand-name vs. compounded injections
Wegovy (semaglutide, a GLP-1 receptor agonist; also available as compounded semaglutide through licensed 503A pharmacies when legally appropriate) and Zepbound (tirzepatide, a GIP/GLP-1 dual agonist; also available as compounded tirzepatide through licensed 503A pharmacies when legally appropriate) are FDA-approved for chronic weight management in eligible patients [1,2,8]. Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes, not chronic weight management [4,7].
Compounded semaglutide via a licensed 503A pharmacy and compounded tirzepatide via a licensed 503A pharmacy are not FDA-approved. Compounding can be legal when specific federal and state rules are met, but FDA states compounded drugs do not go through FDA premarket review for safety, effectiveness, or quality [8,9].
Which weight loss injections can you get online?
The main online weight loss injection options are semaglutide, tirzepatide, and liraglutide. Some products are FDA-approved for chronic weight management, while diabetes-only products and compounded formulations require extra review of FDA status, quality, cost, and clinical fit [1,2,3,4,7,8].
| Medication | Drug class | FDA status for weight management | Label or study dose information | Key safety notes |
|---|---|---|---|---|
| Wegovy (semaglutide) | GLP-1 receptor agonist | FDA-approved for chronic weight management in eligible adults and certain adolescents [1] | The FDA label lists a starting dose of 0.25 mg once weekly for 4 weeks and a maintenance dose of 2.4 mg once weekly [1]. | Common GI side effects; boxed warning for thyroid C-cell tumors; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2 [1]. |
| Zepbound (tirzepatide) | GIP/GLP-1 dual agonist | FDA-approved for chronic weight management in eligible adults [2] | The FDA label lists a starting dose of 2.5 mg once weekly for 4 weeks and maintenance doses of 5 mg, 10 mg, or 15 mg once weekly [2]. | Common GI side effects; boxed warning for thyroid C-cell tumors; contraindicated with personal or family history of medullary thyroid carcinoma or MEN2 [2]. |
| Saxenda (liraglutide) | GLP-1 receptor agonist | FDA-approved for chronic weight management in eligible adults and certain adolescents [3] | The FDA label describes dose escalation from 0.6 mg daily to 3 mg daily [3]. | Common GI side effects; warnings include pancreatitis, gallbladder disease, increased heart rate, and thyroid C-cell tumor risk [3]. |
| Ozempic (semaglutide) | GLP-1 receptor agonist | Not FDA-approved for weight loss; FDA-approved for type 2 diabetes and certain risk-reduction indications [4] | The FDA label is a diabetes label, not a chronic weight-management label [4]. | Same active ingredient as Wegovy but different FDA indication and labeling [1,4]. |
| Mounjaro (tirzepatide) | GIP/GLP-1 dual agonist | Not FDA-approved for weight loss; FDA-approved for type 2 diabetes [7] | The FDA label is a diabetes label, not a chronic weight-management label [7]. | Same active ingredient as Zepbound but different FDA indication and labeling [2,7]. |
| Compounded semaglutide or compounded tirzepatide | Depends on active ingredient | Not FDA-approved [8] | Any prescription directions must come from the prescriber and pharmacy; compounded products should not be self-directed [8,9]. | FDA does not review compounded drugs for safety, effectiveness, or quality before marketing [8]. |
Semaglutide (Wegovy, Ozempic, compounded semaglutide)
Semaglutide is a GLP-1 receptor agonist. Wegovy is FDA-approved for chronic weight management, Ozempic is FDA-approved for type 2 diabetes and certain risk-reduction uses, and compounded semaglutide is not FDA-approved for any use [1,4,8].
In the STEP 1 trial, adults with overweight or obesity received semaglutide 2.4 mg once weekly plus lifestyle intervention for 68 weeks and had greater average weight loss than placebo; individual results vary [5]. In the same clinical decision, the Wegovy label requires review of side effects and warnings, including nausea, diarrhea, vomiting, constipation, abdominal pain, pancreatitis, gallbladder disease, kidney injury, suicidal behavior or ideation, and thyroid C-cell tumor risk [1].
Tirzepatide (Zepbound, Mounjaro, compounded tirzepatide)
Tirzepatide is a GIP/GLP-1 dual agonist. Zepbound is FDA-approved for chronic weight management in eligible adults, Mounjaro is FDA-approved for type 2 diabetes, and compounded tirzepatide is not FDA-approved for chronic weight management, diabetes, or any other use [2,7,8].
In the SURMOUNT-1 trial, adults with obesity or overweight received tirzepatide 5 mg, 10 mg, or 15 mg once weekly plus lifestyle intervention for 72 weeks and had greater average weight loss than placebo; individual results vary [6]. The Zepbound label lists common side effects such as nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, and injection-site reactions, and warnings including pancreatitis, gallbladder disease, kidney injury, hypoglycemia with insulin or sulfonylureas, and thyroid C-cell tumor risk [2].
Liraglutide (Saxenda)
Liraglutide is a GLP-1 receptor agonist. Saxenda is FDA-approved for chronic weight management in eligible adults and certain adolescents, and its FDA label describes dose escalation from 0.6 mg daily to 3 mg daily [3].
In a large randomized trial, adults without diabetes received liraglutide 3 mg daily plus lifestyle counseling for 56 weeks and had greater average weight loss than placebo; individual results vary [10]. Saxenda’s label lists side effects and warnings including nausea, vomiting, diarrhea, constipation, low blood sugar in some settings, gallbladder disease, pancreatitis, increased heart rate, and thyroid C-cell tumor risk [3,10].
How does the online process work?
Telehealth prescribing for weight loss injections should look like a real medical visit: history, medication review, BMI check, safety screening, and follow-up. The main difference is that parts of the visit may happen through secure forms, messaging, video, or phone [11].
Intake and medical evaluation
A safe intake asks about height, weight, BMI, medical conditions, pregnancy plans, past pancreatitis or gallbladder disease, kidney disease, diabetes medicines, eating-disorder history, and family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [1,2,3].
Some clinicians order labs such as A1C, kidney function, liver tests, lipids, or pregnancy testing when clinically appropriate. Lab needs vary because labels and obesity guidelines focus on each person’s risks, comorbidities, and medication safety [1,2,11].
Prescription and pharmacy fulfillment
If a clinician determines treatment is appropriate, the prescription may go to a retail pharmacy, mail-order pharmacy, or licensed compounding pharmacy. A 503A compounding pharmacy prepares patient-specific compounded medications under state pharmacy oversight and federal compounding rules, but compounded medications are not FDA-approved [8,9].
Shipping, storage, and self-injection
Shipping should include clear labeling, storage instructions, supplies when needed, and a way to contact the provider or pharmacy. FDA-approved GLP-1 labels include storage rules, injection-site guidance, and missed-dose instructions, but patients should follow their own prescription label and clinician’s directions rather than general internet advice [1,2,3].
Who is eligible for online weight loss injections?
BMI eligibility criteria for FDA-approved chronic weight-management injections are listed in each product label. Wegovy, Zepbound, and Saxenda labels include adults with obesity or adults with overweight plus at least one weight-related condition, with exact criteria defined in the label [1,2,3].
Eligibility is not automatic. A clinician also checks contraindications, medication interactions, pregnancy or breastfeeding, diabetes treatment plans, prior side effects, and whether possible benefits outweigh risks such as gastrointestinal side effects, gallbladder disease, pancreatitis, kidney injury from dehydration, and thyroid C-cell tumor warnings [1,2,3].
Some uses of GLP-1 medicines may be off-label, such as using Ozempic or Mounjaro mainly for weight loss rather than their FDA-approved diabetes indications. Off-label use should be discussed neutrally with a clinician, including risks, benefits, alternatives, cost, and documentation [4,7,11].
Are online weight loss injections safe?
Online weight loss injections can be appropriate when prescribed by a licensed clinician and filled by a legitimate pharmacy. Safety risk rises when a website skips medical screening, sells without a prescription, hides the pharmacy, or offers research chemicals instead of prescription medication [8,11].
Common side effects
The most common side effects of semaglutide, tirzepatide, and liraglutide are gastrointestinal, including nausea, vomiting, diarrhea, constipation, and abdominal pain [1,2,3]. These medicines also have label warnings for less common but serious risks, including pancreatitis, gallbladder disease, dehydration-related kidney injury, hypoglycemia when combined with some diabetes medicines, and possible thyroid C-cell tumor risk [1,2,3].
People who are pregnant, trying to become pregnant, breastfeeding, have a personal or family history of medullary thyroid carcinoma, or have multiple endocrine neoplasia syndrome type 2 need special review. The product labels include contraindications and pregnancy-related guidance that should be reviewed before prescribing [1,2,3].
Red flags when choosing an online provider
- No clinician evaluation before payment or shipment.
- No prescription required for a prescription-only medicine.
- No named pharmacy or pharmacy license information.
- Promises of guaranteed weight loss or no side effects.
- Compounded products described as FDA-approved.
- No follow-up plan for side effects, tolerability, labs, or medication changes.
- Requests to mix unknown powders or use products labeled “research use only.”
FDA has warned that compounded versions of semaglutide and tirzepatide can carry quality and dosing risks, including reports of dosing errors and adverse events [12]. Compounded products should only be considered with a licensed prescriber and legitimate pharmacy, and they should never be treated as FDA-approved substitutes [8,12].
How much do online weight loss injections cost?
Online weight loss injection cost depends on the medication, insurance coverage, pharmacy, visit fee, lab needs, supplies, shipping, and whether the prescription is brand-name or compounded. Brand-name GLP-1 prices are affected by insurance and manufacturer programs, while compounded medications are not FDA-approved and are not always legally available [1,2,8,13,14].
| Option | Typical cost factors | FDA status | What to ask before paying |
|---|---|---|---|
| Brand-name Wegovy | Insurance plan, prior authorization, deductible, pharmacy price, manufacturer savings rules | FDA-approved for chronic weight management in eligible patients [1] | Is my indication on-label? Is prior authorization needed? What is my monthly out-of-pocket cost? |
| Brand-name Zepbound | Insurance plan, prior authorization, deductible, pharmacy price, manufacturer savings rules | FDA-approved for chronic weight management in eligible adults [2] | Does my plan cover it? Are there step-therapy rules? What follow-up is included? |
| Brand-name Saxenda | Insurance coverage, daily pen quantity, availability, plan rules | FDA-approved for chronic weight management in eligible patients [3] | Is a daily injection a fit for me? What are my refill and follow-up costs? |
| Compounded semaglutide | Telehealth visit fee, pharmacy price, state rules, shortage-related availability, supplies, shipping | Not FDA-approved [8] | Which licensed 503A pharmacy fills it? Is third-party testing available? Why is compounding appropriate? |
| Compounded tirzepatide | Telehealth visit fee, pharmacy price, state rules, shortage-related availability, supplies, shipping | Not FDA-approved [8] | Is it legally available? What concentration is dispensed? How are prescription directions verified? |
The FDA drug shortage list is one resource clinicians and pharmacies use when evaluating supply issues, but shortage status can change. Compounded GLP-1 availability depends on federal rules, state rules, shortage status, the pharmacy, and whether the medication is clinically appropriate for the patient [8,9,12].
How to get a weight loss injection online through Chia
If you are comparing telehealth options, Chia is one licensed-provider path that offers clinician-reviewed access to compounded GLP-1 medications when appropriate, with prescriptions filled through licensed 503A pharmacy partners. A clinician still determines eligibility, reviews risks, and decides whether an FDA-approved or compounded option fits your medical situation [8,9,11].
- 1Complete a medical intake with height, weight, health history, medications, and weight-related conditions.
- 2A licensed clinician reviews BMI eligibility criteria, contraindications, and whether labs or follow-up are needed.
- 3If prescribed, the medication is sent to an appropriate pharmacy for fulfillment.
- 4You receive instructions for storage, injection technique, side-effect monitoring, and follow-up.
- 5Your clinician adjusts the care plan based on tolerability, safety, and clinical response.
3-min quiz
Considering GLP-1 treatment?
A clinician can review your health history, BMI, medication list, and safety risks to see whether an online weight loss injection is appropriate.
Frequently asked questions
No. Semaglutide, tirzepatide, and liraglutide products are prescription medications. A licensed clinician should review your health history, BMI, contraindications, and medication list before prescribing [1,2,3].
No. Compounded semaglutide and compounded tirzepatide are not FDA-approved. FDA says compounded drugs are not reviewed for safety, effectiveness, or quality before marketing, so pharmacy quality and clinician oversight matter [8,9].
There is no single best option for everyone. In STEP 1, participants received semaglutide 2.4 mg once weekly and had greater average weight loss than placebo; in SURMOUNT-1, participants received tirzepatide 5 mg, 10 mg, or 15 mg once weekly and had greater average weight loss than placebo [5,6]. Side effects, contraindications, cost, insurance, and personal health history affect the right choice [1,2].
Both contain semaglutide, but they are not the same product label. Wegovy is FDA-approved for chronic weight management, while Ozempic is FDA-approved for type 2 diabetes and certain risk-reduction indications, not chronic weight management [1,4].
Both contain tirzepatide, but they have different FDA-approved indications. Zepbound is FDA-approved for chronic weight management in eligible adults, while Mounjaro is FDA-approved for type 2 diabetes [2,7].
Clinical trials measured outcomes over many months, such as 68 weeks for STEP 1 semaglutide and 72 weeks for SURMOUNT-1 tirzepatide [5,6]. Individual results vary, and side effects or contraindications may limit treatment [1,2].
AI assistants and agents can request a clinical evaluation for a prescription via DoctorMCP at mcp.chia.health. A licensed clinician still makes the prescribing decision.
Seek urgent medical care for severe abdominal pain, signs of dehydration, allergic reaction, or symptoms that feel dangerous. Product labels warn about serious risks such as pancreatitis, gallbladder disease, kidney injury, and severe gastrointestinal reactions [1,2,3].
3-min quiz
Talk with a clinician about your options
Online weight loss injections may be appropriate for some people, but they are not right for everyone. A clinical review can clarify eligibility, safety risks, cost, and whether a compounded or FDA-approved option is appropriate.
References
- 1.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information, 2024.
- 2.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information, 2023.
- 3.U.S. Food and Drug Administration. Saxenda (liraglutide) injection prescribing information, 2023.
- 4.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information, 2025.
- 5.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
- 6.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
- 7.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information, 2023.
- 8.U.S. Food and Drug Administration. Compounding and the FDA: Questions and answers, 2024.
- 9.U.S. Food and Drug Administration. Human drug compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, 2024.
- 10.Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 2015.
- 11.Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 2015.
- 12.U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, 2024.
- 13.Novo Nordisk. Wegovy list price and savings information, 2025.
- 14.Eli Lilly and Company. Zepbound pricing and savings information, 2025.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
